


Patent Docket P1467R2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|--|--|
| <p>In re Application of Camellia W. Adams et al. Serial No.: 09/602,812 Filed: June 23, 2000 For: Humanized Anti-ErbB2 Antibodies and Treatment with Anti-ErbB2 Antibodies</p> | <p>Group Art Unit: 1642 Examiner: Anne Holleran Certificate of Facsimile Transmission Under 37 CFR § 1.8 In accordance with CFR § 1.8(d), this correspondence addressed to The Patent and Trademark Office, Washington, DC 20231 is being transmitted to facsimile No. (703) 746-4989 May 6, 2003  Wendy M. Lee</p> |
|--|--|

AMENDMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Further to the amendment dated March 24, 2003 and in consideration of the interview April 28, 2003, please amend the pending claims as follows.

D1
27. (Amended) A method of treating cancer in a human, wherein the cancer expresses but does not overexpress ErbB2 receptor, comprising administering to the human a therapeutically effective amount of an antibody which binds to ErbB2 and blocks ligand activation of an ErbB receptor more effectively than monoclonal antibody 4D5.

D2
34. (Amended) A method of treating cancer in a human, wherein the cancer is selected from the group consisting of colon, rectal and colorectal cancer which express ErbB2, comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2 and blocks ligand activation of an ErbB receptor more effectively than monoclonal antibody 4D5.

D3
60. (Amended) A method of treating cancer in a human, wherein the cancer expresses epidermal growth factor receptor (EGFR) and ErbB2, comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2 and blocks TGF- α activation of mitogen-activated protein kinase (MAPK) more effectively than monoclonal antibody 4D5.